

# Franz H Messerli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4362416/publications.pdf>

Version: 2024-02-01

227  
papers

22,382  
citations

18482

62  
h-index

8630

146  
g-index

234  
all docs

234  
docs citations

234  
times ranked

22103  
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of pulse pressure at low systolic blood pressure. <i>European Heart Journal</i> , 2022, 43, 540-540.	2.2	2
2	Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?. <i>Circulation</i> , 2022, 145, 413-415.	1.6	9
3	Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?. <i>Global Heart</i> , 2022, 17, 17.	2.3	4
4	Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e319-e322.	1.8	2
5	Safety and Efficacy of Thiazide Diuretics in Hypertension. <i>American Journal of Medicine</i> , 2022, 135, e109.	1.5	0
6	Sutton's law and dietary Na <sup>+</sup> /K <sup>+</sup> intake in cardiovascular disease. <i>European Heart Journal</i> , 2022, 43, 2876-2877.	2.2	2
7	Sodium intake, life expectancy, and all-cause mortality. <i>European Heart Journal</i> , 2021, 42, 2103-2112.	2.2	46
8	Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects. <i>Journal of Hypertension</i> , 2021, 39, 1254-1260.	0.5	11
9	Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. <i>Journal of Hypertension</i> , 2021, 39, 784-794.	0.5	34
10	MANAGEMENT OF CLOT IN TRANSIT IN A POST-PARTUM COVID-19 PATIENT. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2920.	2.8	1
11	Salt consumption at a population level remains remarkably steady over time. <i>European Heart Journal</i> , 2021, 42, 2134-2134.	2.2	1
12	Alcohol and atrial fibrillation: not all drinks are created equal. <i>European Heart Journal</i> , 2021, 42, 2506-2506.	2.2	2
13	Ivabradine in POTS. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3141-3142.	2.8	1
14	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. <i>European Heart Journal</i> , 2021, 42, 2052-2059.	2.2	1
15	Social media and predictive analysis regarding dietary approaches to stop hypertension. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 88-90.	3.1	0
16	Soluble fms-like tyrosine kinase 1 (sFlt-1): A novel biochemical marker for acute fatty liver of pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1876-1884.	2.8	3
17	Reply. <i>Journal of Hypertension</i> , 2021, 39, 1726-1727.	0.5	0
18	Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study. <i>European Heart Journal</i> , 2021, 42, 4282.	2.2	1

#	ARTICLE	IF	CITATIONS
19	On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics. European Heart Journal, 2021, 42, 758-760.	2.2	9
20	Optimal BP Targets to Prevent Stroke and MI. Journal of the American College of Cardiology, 2021, 78, 1679-1681.	2.8	8
21	Implications of Guideline Updates for the Management of Apparent Treatment Resistant Hypertension in the United States (A NCDR Research to Practice [R2P] Project). American Journal of Cardiology, 2020, 125, 63-67.	1.6	3
22	Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics. International Journal of Cardiology: Hypertension, 2020, 7, 100054.	2.2	1
23	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	2.2	103
24	Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension. JAMA Internal Medicine, 2020, 180, 1133.	5.1	2
25	Letter by Messerli et al Regarding Article, "Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort". Circulation, 2020, 142, e27-e28.	1.6	1
26	Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2934-2936.	2.9	3
27	Non-invasive pulmonary artery pressure estimation by electrical impedance tomography in a controlled hypoxemia study in healthy subjects. Scientific Reports, 2020, 10, 21462.	3.3	11
28	Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis. Progress in Cardiovascular Diseases, 2020, 63, 527-528.	3.1	21
29	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Progress in Cardiovascular Diseases, 2020, 63, 682-689.	3.1	221
30	Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiology, 2020, 5, 745.	6.1	197
31	Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?. Journal of the American Heart Association, 2020, 9, e016509.	3.7	210
32	The muddy waters of the J-curve and coronary revascularization. European Heart Journal, 2020, 41, 1684-1686.	2.2	9
33	COVID-19 and Renin Angiotensin Blockers. Circulation, 2020, 141, 2042-2044.	1.6	33
34	Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?. Cleveland Clinic Journal of Medicine, 2020, 87, 9.1-9.	1.3	0
35	Blood Pressure Variability and Arterial Stiffness "Chicken or Egg?". JAMA Cardiology, 2019, 4, 1050.	6.1	10
36	Renin-Angiotensin-Aldosterone Axis Modulators and Other Vasodilators. Contemporary Cardiology, 2019, , 61-72.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Beta Blockers and Calcium Channel Blockers. Contemporary Cardiology, 2019, , 73-88.	0.1	1
38	Postholiday Heart Failure Triggered by Dietary Salt Excess. JAMA Internal Medicine, 2019, 179, 1006.	5.1	0
39	Ephemeral Coronary Heart Disease. European Heart Journal, 2019, 40, 1906-1908.	2.2	3
40	Risk Factor Variability and Cardiovascular Outcome. Journal of the American College of Cardiology, 2019, 73, 2596-2603.	2.8	60
41	Letter by Messerli et al Regarding Article "Early Life Factors and Longitudinal Blood Pressure Trajectories Are Associated With Elevated Blood Pressure in Early Adulthood: BT20 Cohort", Hypertension, 2019, 73, e83.	2.7	1
42	Of headwind and tailwind, regression to the mean and Wilder's principle. Journal of Hypertension, 2019, 37, 4-5.	0.5	5
43	The alcohol blood pressure paradox. European Heart Journal, 2019, 40, 711-712.	2.2	5
44	Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?. European Heart Journal, 2019, 40, 1787-1789.	2.2	15
45	Letter by Messerli and Bangalore Regarding Article, "Association of Blood Pressure Measurements With Peripheral Artery Disease Events", Circulation, 2019, 139, 1854-1854.	1.6	0
46	Misconceptions and Facts About Beta-Blockers. American Journal of Medicine, 2019, 132, 816-819.	1.5	23
47	Stable coronary artery disease. Journal of Hypertension, 2019, 37, 1112-1118.	0.5	10
48	Systolic Hypertension, Preeclampsia-Related Mortality, and Stroke In California. Obstetrics and Gynecology, 2019, 134, 880-880.	2.4	2
49	Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia. Journal of Hypertension, 2019, 37, 1012-1017.	0.5	22
50	Peripheral edema and headache associated with amlodipine treatment. Journal of Hypertension, 2019, 37, 2093-2103.	0.5	9
51	How much salt is too much salt?. Anatolian Journal of Cardiology, 2019, 22, 2-4.	0.9	0
52	Changing definition of hypertension in guidelines: how innocent a number game?. European Heart Journal, 2018, 39, 2241-2242.	2.2	23
53	Hypothyroidism and hypertension: fact or myth?. Lancet, The, 2018, 391, 29-30.	13.7	9
54	Lowering the Thresholds of Diseases. Journal of the American College of Cardiology, 2018, 71, 119-121.	2.8	8

#	ARTICLE	IF	CITATIONS
55	The Reply. American Journal of Medicine, 2018, 131, e27.	1.5	0
56	Angiotensin-Converting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology, 2018, 71, 1474-1482.	2.8	215
57	What Ever Happened to Cardioprotection With Î²-Blockers?. Mayo Clinic Proceedings, 2018, 93, 401-403.	3.0	4
58	Alter ego(s) in coronary artery disease. European Heart Journal, 2018, 39, 3987-3998.	2.2	1
59	Reply. JACC: Heart Failure, 2018, 6, 890.	4.1	0
60	In Hypertension as Elsewhere in Medicine, One Size Does Not Fit All. Hypertension, 2018, 72, 829-831.	2.7	0
61	Association of Assisted Reproductive Technologies With Arterial Hypertension During Adolescence. Journal of the American College of Cardiology, 2018, 72, 1267-1274.	2.8	123
62	The Blood Pressure Landscape. Journal of the American College of Cardiology, 2018, 72, 1313-1316.	2.8	20
63	The oldest old: does hypertension become essential again?. European Heart Journal, 2018, 39, 3144-3146.	2.2	10
64	When Guideline Authors Ignore Their Own Guidelines. Hypertension, 2018, 72, e19.	2.7	0
65	GaisbÃ¼ck syndrome (polycythemia and hypertension) revisited. Journal of Hypertension, 2018, 36, 2420-2424.	0.5	9
66	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	3.5	62
67	Age, Cardiovascular Risk, and Blood Pressure Target. Journal of the American College of Cardiology, 2018, 72, 818-819.	2.8	0
68	Age, Blood Pressure Targets, and Guidelines. Circulation, 2018, 138, 128-130.	1.6	16
69	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
70	Salt and heart disease: a second round of â€œbad scienceâ€?. Lancet, The, 2018, 392, 456-458.	13.7	33
71	Ivabradine in Coronary Heart Diseaseâ€”The Emperor Has No Clothes. American Journal of Cardiology, 2017, 120, e15.	1.6	2
72	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. American Journal of Medicine, 2017, 130, 707-719.e8.	1.5	142

#	ARTICLE	IF	CITATIONS
73	Salt, Tomato Soup, and the Hypocrisy of the American Heart Association. American Journal of Medicine, 2017, 130, 392-393.	1.5	5
74	Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. Journal of the American College of Cardiology, 2017, 69, 486-493.	2.8	117
75	Hypertension control and cardiovascular disease. Lancet, The, 2017, 389, 153.	13.7	12
76	Letter by Messerli et al Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure" Circulation, 2017, 135, e45-e46.	1.6	8
77	Salt and Blood Pressure: Cutting Through the Scientific Fog. Current Hypertension Reports, 2017, 19, 47.	3.5	1
78	Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2017, 130, 1325.e1-1325.e12.	1.5	14
79	Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. Circulation, 2017, 135, 2085-2087.	1.6	32
80	Observations on the blood pressure paradox in heart failure. European Journal of Heart Failure, 2017, 19, 843-845.	7.1	13
81	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 376, 1332-1340.	27.0	229
82	Safety vs Efficacy of Lowering Blood Pressure. JAMA Cardiology, 2017, 2, 1398.	6.1	0
83	Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2458.	2.8	1
84	Hypothyroidism as a cause of secondary hypertension - Myth dispelled. Journal of the American Society of Hypertension, 2017, 11, 615.	2.3	2
85	Renal denervation: will the Phoenix rise from the ashes?. European Heart Journal, 2017, 38, 3321-3323.	2.2	1
86	The Reply. American Journal of Medicine, 2017, 130, e321.	1.5	0
87	Reply. Journal of the American College of Cardiology, 2017, 70, 510.	2.8	5
88	The Transition From Hypertension to Heart Failure. JACC: Heart Failure, 2017, 5, 543-551.	4.1	305
89	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.5	0
90	Reply. JACC: Heart Failure, 2017, 5, 851.	4.1	0

#	ARTICLE	IF	CITATIONS
91	In polypills, as in any recipe, it's ingredients that matter. Journal of Hypertension, 2017, 35, 2550.	0.5	1
92	Reply. Journal of the American College of Cardiology, 2017, 70, 120.	2.8	5
93	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 377, 94-96.	27.0	15
94	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	2.7	4
95	Are ACE inhibitors acceptable ingredients in polypills?. Lancet, The, 2017, 390, 26.	13.7	3
96	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.5	12
97	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. American Journal of Cardiology, 2017, 119, 379-387.	1.6	58
98	Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ: British Medical Journal, 2017, 356, j4.	2.3	69
99	Introduction: Controversies in Hypertension. Progress in Cardiovascular Diseases, 2016, 59, 207-208.	3.1	7
100	Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle?. American Journal of Medicine, 2016, 129, 769-770.	1.5	13
101	Misconceptions and Facts About Mitral Regurgitation. American Journal of Medicine, 2016, 129, 919-923.	1.5	3
102	Serum Uric Acid in Primary Hypertension. Hypertension, 2016, 67, 845-847.	2.7	10
103	Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease. Hypertension, 2016, 67, 1205-1210.	2.7	32
104	Reply. Journal of the American College of Cardiology, 2016, 68, 430-431.	2.8	1
105	When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. Journal of the American College of Cardiology, 2016, 68, 754-762.	2.8	52
106	Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients ≥65 Years of Age. American Journal of Cardiology, 2016, 118, 1427-1436.	1.6	11
107	Isolated Systolic Hypertension: An Update After SPRINT. American Journal of Medicine, 2016, 129, 1251-1258.	1.5	85
108	In Reply "The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality. Mayo Clinic Proceedings, 2016, 91, 972-975.	3.0	1

#	ARTICLE	IF	CITATIONS
109	Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?. Progress in Cardiovascular Diseases, 2016, 59, 253-261.	3.1	38
110	Cognitive Decline, Blood Pressure Control and Variability: A Relentless Downward Spiral?. Journal of the American Medical Directors Association, 2016, 17, 1160-1161.	2.5	0
111	Heart rate lowering by beta-blockade and cardiovascular events. Journal of Hypertension, 2016, 34, 2102-2103.	0.5	2
112	Adverse effects and tolerability of $\beta^2$ blockers. BMJ, The, 2016, 353, i3142.	6.0	4
113	Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology, 2016, 67, 379-389.	2.8	74
114	Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, The, 2016, 352, i438.	6.0	135
115	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clinic Proceedings, 2016, 91, 51-60.	3.0	86
116	Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. American Journal of Medicine, 2016, 129, 635.e5-635.e14.	1.5	27
117	The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo. Annals of Translational Medicine, 2016, 4, 321-321.	1.7	0
118	Quo usque tandem abutere, Catilina, patientia nostra?. Swiss Medical Weekly, 2016, 146, w14344.	1.6	1
119	Efficacy and Safety of Calcium Channel Blocker/Diuretics Combination Therapy in Hypertensive Patients: A Meta-Analysis. Journal of Clinical Hypertension, 2015, 17, 193-199.	2.0	27
120	Feto-maternal interactions. Current Opinion in Cardiology, 2015, 30, 391-392.	1.8	1
121	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	2.5	4
122	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 809-817.	1.6	56
123	Efficacy of folic acid in primary prevention of stroke among patients with hypertension in China. Journal of the American Society of Hypertension, 2015, 9, 665-667.	2.3	2
124	Futility of Imaging Atherosclerotic Renal Artery Stenosis?. American Journal of Medicine, 2015, 128, e25.	1.5	0
125	Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal, 2015, 36, 576-579.	2.2	55
126	Drug induced hypertension – An unappreciated cause of secondary hypertension. European Journal of Pharmacology, 2015, 763, 15-22.	3.5	64



#	ARTICLE	IF	CITATIONS
127	Misconceptions and Facts About Treating Hypertension. American Journal of Medicine, 2015, 128, 450-455.	1.5	7
128	Optimal blood pressure targets in 2014 – Does the guideline recommendation match the evidence base?. Hipertension Y Riesgo Vascular, 2015, 32, 71-82.	0.6	0
129	Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. Journal of the American College of Cardiology, 2015, 65, 1539-1548.	2.8	156
130	Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. European Heart Journal, 2015, 36, 1967-1973.	2.2	87
131	Resistant hypertension: what the cardiologist needs to know. European Heart Journal, 2015, 36, 2686-2695.	2.2	40
132	Letter by Argulian and Messerli Regarding Article, “Effect of Early Metoprolol on Infarct Size in ST-Segment–Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial”. Circulation, 2014, 130, e18.	1.6	0
133	Renal Denervation for Resistant Hypertension?. New England Journal of Medicine, 2014, 370, 1454-1457.	27.0	62
134	The Reply. American Journal of Medicine, 2014, 127, e19.	1.5	0
135	Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease. American Journal of Medicine, 2014, 127, 71-81.e1.	1.5	77
136	Secondary arterial hypertension: when, who, and how to screen?. European Heart Journal, 2014, 35, 1245-1254.	2.2	258
137	Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. European Heart Journal, 2014, 35, 1801-1808.	2.2	12
138	2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	2.8	67
139	Clinical Outcomes with Î²-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. American Journal of Medicine, 2014, 127, 939-953.	1.5	224
140	Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. European Heart Journal, 2014, 35, 1732-1742.	2.2	28
141	Competing Cardiovascular and Noncardiovascular Risks and Longevity in the Systolic Hypertension in the Elderly Program. American Journal of Cardiology, 2014, 113, 676-681.	1.6	9
142	Left-ventricular hypertrophy in obesity. Journal of Hypertension, 2014, 32, 1542-1543.	0.5	3
143	Erythrocyte Membrane Properties in Patients with Essential Hypertension. Cell Biochemistry and Biophysics, 2013, 67, 1089-1102.	1.8	27
144	Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Failure Reviews, 2013, 18, 429-437.	3.9	18

#	ARTICLE	IF	CITATIONS
145	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
146	Efficacy and Safety of Dual Calcium Channel Blockade for the Treatment of Hypertension: A Meta-Analysis. American Journal of Hypertension, 2013, 26, 287-297.	2.0	13
147	Fraudulent data: an apology and the fate of angiotensin receptor blockers. BMJ, The, 2013, 347, f5549-f5549.	6.0	1
148	Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis. Journal of Clinical Hypertension, 2013, 15, 435-442.	2.0	141
149	Diuretic-based regimens for obese patients?. Lancet, The, 2013, 381, 512-513.	13.7	6
150	Is Dual Renin-Angiotensin-System Blockade Associated With Increased Risk of Stroke?. JACC: Heart Failure, 2013, 1, 454-457.	4.1	0
151	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. European Heart Journal, 2013, 34, 1095-1098.	2.2	16
152	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, The, 2013, 346, f360-f360.	6.0	185
153	Treatment-resistant hypertension: another Cinderella story. European Heart Journal, 2013, 34, 1175-1177.	2.2	12
154	Î²-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	7.4	377
155	Chocolate Consumption, Cognitive Function, and Nobel Laureates. New England Journal of Medicine, 2012, 367, 1562-1564.	27.0	158
156	Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin-Angiotensin System Inhibitors. American Journal of Cardiology, 2012, 110, 383-391.	1.6	145
157	Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. American Journal of Medicine, 2012, 125, 14-22.	1.5	204
158	The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights. Current Atherosclerosis Reports, 2012, 14, 124-129.	4.8	17
159	Cardiovascular Death and Cancer Death—Competing Risk?. American Journal of Cardiology, 2012, 109, 1687.	1.6	0
160	Blood Pressure and Stroke. Journal of the American College of Cardiology, 2011, 57, 114-115.	2.8	3
161	Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology, 2011, 57, 590-600.	2.8	148
162	Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies. American Journal of Medicine, 2011, 124, 896-899.	1.5	59

#	ARTICLE	IF	CITATIONS
163	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. <i>Lancet Oncology</i> , The, 2011, 12, 65-82.	10.7	332
164	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. <i>BMJ: British Medical Journal</i> , 2011, 342, d2234-d2234.	2.3	121
165	Trials on the Effect of Cardiac Resynchronization on Arterial Blood Pressure in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 107, 561-568.	1.6	19
166	Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. <i>European Heart Journal</i> , 2011, 32, 2231-2235.	2.2	141
167	Hypertension management 2011: optimal combination therapy. <i>European Heart Journal</i> , 2011, 32, 2499-2506.	2.2	87
168	Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose. <i>Circulation</i> , 2011, 123, 2799-2810.	1.6	397
169	Beyond salt: lifestyle modifications and blood pressure. <i>European Heart Journal</i> , 2011, 32, 3081-3087.	2.2	111
170	Coronary Revascularization Strategy and Outcomes According to Blood Pressure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 T	1.6	32
171	J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. <i>European Heart Journal</i> , 2010, 31, 2897-2908.	2.2	318
172	The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. <i>European Heart Journal</i> , 2010, 31, 552-560.	2.2	79
173	Of fads, fashion, surrogate endpoints and dual RAS blockade. <i>European Heart Journal</i> , 2010, 31, 2205-2208.	2.2	31
174	Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy. <i>American Journal of Medicine</i> , 2010, 123, 719-726.	1.5	139
175	Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference. <i>American Journal of Medicine</i> , 2010, 123, 1016-1030.	1.5	90
176	Antihypertensive Efficacy of Aliskiren. <i>Circulation</i> , 2009, 119, 371-373.	1.6	21
177	Angiotensin receptor blockers: baseline therapy in hypertension?. <i>European Heart Journal</i> , 2009, 30, 2427-2430.	2.2	28
178	Flash Pulmonary Edema. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 249-259.	3.1	69
179	Simple-Minded Antihypertensive Treatment: Of Assumptions, Potpourri, and Sausages. <i>Journal of Clinical Hypertension</i> , 2009, 11, 702-706.	2.0	1
180	The crumbling of dual renin-angiotensin system blockade. <i>Current Hypertension Reports</i> , 2009, 11, 159-161.	3.5	0

#	ARTICLE	IF	CITATIONS
181	Cardioprotection with beta-blockers: myths, facts and Pascal's wager. <i>Journal of Internal Medicine</i> , 2009, 266, 232-241.	6.0	30
182	The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point. <i>Journal of the American College of Cardiology</i> , 2009, 53, 468-470.	2.8	63
183	Beta-Blockers as First-Line Antihypertensive Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1162-1164.	2.8	18
184	The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1827-1834.	2.8	213
185	$\beta_2$ -Blockers: No longer an option for uncomplicated hypertension. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 280-285.	2.0	1
186	$\beta_2$ -blockers as fourth-line therapy for hypertension: stay the course. <i>International Journal of Clinical Practice</i> , 2008, 62, 1643-1646.	1.7	13
187	Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1062-1072.	2.8	90
188	Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1482-1489.	2.8	191
189	Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An International Verapamil SR-Trandolapril (INVEST) substudy. <i>American Heart Journal</i> , 2008, 156, 241-247.	2.7	48
190	When Guidelines Need Guidance. <i>American Journal of Medicine</i> , 2008, 121, 742-743.	1.5	8
191	Risk/Benefit Assessment of $\beta_2$ -Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. <i>Circulation</i> , 2008, 117, 2706-2715.	1.6	117
192	Antihypertensive properties of a high-dose combination of trandolapril and verapamil SR. <i>Blood Pressure</i> , 2007, 16, 6-9.	1.5	4
193	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007, 50, 299-305.	2.7	174
194	Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. <i>American Journal of Medicine</i> , 2007, 120, 713-719.	1.5	900
195	Body Weight Changes with $\beta_2$ -Blocker Use: Results from GEMINI. <i>American Journal of Medicine</i> , 2007, 120, 610-615.	1.5	95
196	Blood pressure, cognitive dysfunction, and dementia. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 135-144.	2.3	13
197	Essential hypertension. <i>Lancet</i> , The, 2007, 370, 591-603.	13.7	574
198	Cardiovascular Protection Using Beta-Blockers. <i>Journal of the American College of Cardiology</i> , 2007, 50, 563-572.	2.8	214

#	ARTICLE	IF	CITATIONS
199	Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. Blood Pressure Supplement, 2007, 1, 6-9.	0.2	0
200	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?. Annals of Internal Medicine, 2006, 144, 884.	3.9	664
201	When premature is not prematureâ€”the ASCOT studyThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1822-1823.	2.2	4
202	Cerebroprotection mediated by angiotensin II. Journal of the American College of Cardiology, 2004, 43, 1343-1347.	2.8	122
203	Evolution of calcium antagonists: Past, present, and future. Clinical Cardiology, 2003, 26, 12-16.	1.8	24
204	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. American Journal of Medicine, 2003, 115, 41-46.	1.5	686
205	A Calcium Antagonist vs a Nonâ€”Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	7.4	1,107
206	Do Thiazide Diuretics Confer Specific Protection Against Strokes?. Archives of Internal Medicine, 2003, 163, 2557.	3.8	35
207	The LIFE study: the straw that should break the camel's back. European Heart Journal, 2003, 24, 487-489.	2.2	14
208	Blood pressure control in stroke patients. Neurology, 2002, 59, 23-25.	1.1	29
209	Calcium antagonists in hypertension: from hemodynamics to outcomes. American Journal of Hypertension, 2002, 15, S94-S97.	2.0	31
210	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 1133-1134.	1.6	9
211	Vasodilatory edema: A common side effect of antihypertensive therapy. Current Cardiology Reports, 2002, 4, 479-482.	2.9	116
212	Antihypertensive Therapy: Beta-Blockers and Diureticsâ€”Why Do Physicians Not Always Follow Guidelines?. Baylor University Medical Center Proceedings, 2000, 13, 128-134.	0.5	10
213	Angiotensin II Receptor Blockers. Archives of Internal Medicine, 2000, 160, 1905.	3.8	53
214	Vasopeptidase inhibition and angio-oedema. Lancet, The, 2000, 356, 608-609.	13.7	215
215	.â€”%â€”%â€”%. And losartan was no better than placebo. Journal of Human Hypertension, 1999, 13, 649-650.	2.2	12
216	Framingham at 50. Lancet, The, 1998, 352, 1006.	13.7	15

#	ARTICLE	IF	CITATIONS
217	Comparative Tolerability Profile of Hypertensive Crisis Treatments. Drug Safety, 1998, 19, 99-122.	3.2	61
218	Are $\beta_2$ -Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?. JAMA - Journal of the American Medical Association, 1998, 279, 1903.	7.4	488
219	Angiotensin II Receptor Inhibition. Archives of Internal Medicine, 1996, 156, 1957.	3.8	91
220	Introduction: Antihypertensive therapy: Past, present, and future. Cardiovascular Drugs and Therapy, 1994, 8, 7-9.	2.6	0
221	Antihypertensive Therapy Is it Different in the Elderly?. Drugs, 1990, 39, 49-54.	10.9	8
222	Disparate Cardiovascular Findings in Men and Women with Essential Hypertension. Annals of Internal Medicine, 1987, 107, 158.	3.9	141
223	Osler's Maneuver and Pseudohypertension. New England Journal of Medicine, 1985, 312, 1548-1551.	27.0	213
224	Cardiovascular Pathophysiology of Essential Hypertension. Drugs, 1985, 30, 25-34.	10.9	19
225	Arterial Compliance in Systolic Hypertension. Clinical and Experimental Hypertension, 1982, 4, 1037-1044.	0.3	18
226	Individualization of Antihypertensive Therapy: An Approach Based on Hemodynamics and Age. Journal of Clinical Pharmacology, 1981, 21, 517-528.	2.0	23
227	Serum Uric Acid in Essential Hypertension: An Indicator of Renal Vascular Involvement. Annals of Internal Medicine, 1980, 93, 817.	3.9	375